Suthanthiran M, Strom T B
Department of Transplantation and Extracorporeal Therapy, Rogosin Institute, New York Hospital-Cornell Medical Center, New York, USA.
J Clin Immunol. 1995 Jul;15(4):161-71. doi: 10.1007/BF01541085.
Much has been learned regarding immunobiological mechanisms responsible for the rejection of histoincompatible allografts. There has also been considerable progress in our understanding of mechanisms responsible for tolerance. The new knowledge gained regarding graft destructive alloimmunity process and the mechanisms of action of immunosuppressants have resulted in solid organ graft survival rates that are in excess of 80% at one year posttransplantation. The principles of tolerance mechanism are yet to be successfully applied in the clinic. In this review, molecular and cellular mechanisms of action of clinically useful immunosuppressive drugs are reviewed from the perspective of regulation of the anti-allograft repertory.
关于负责组织不相容同种异体移植物排斥反应的免疫生物学机制，我们已经了解了很多。在我们对耐受机制的理解方面也取得了相当大的进展。关于移植物破坏性同种异体免疫过程以及免疫抑制剂作用机制所获得的新知识，已使实体器官移植术后一年的存活率超过80%。耐受机制的原理尚未成功应用于临床。在本综述中，我们从调节抗同种异体移植反应库的角度，综述了临床有用的免疫抑制药物的分子和细胞作用机制。
